OncoMatch/Clinical Trials/NCT06908031
SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer
Is NCT06908031 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including PD-1 monoclonal antibody and mFOLFOX6 regimen for rectal adenocarcinoma.
Treatment: PD-1 monoclonal antibody · mFOLFOX6 regimen · Cetuximab · Bevacizumab — To explore the efficacy and safety of short-course radiotherapy combined with mFOLFOX6, PD-1 monoclonal antibody and cetuximab (for RAS/BRAF Wild-Type)/bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma through a prospective study, providing high-level evidence-based medical evidence for the use in the treatment of high-risk rectal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MMR proficient
pMMR
Required: MSH2 microsatellite stable
MSS
Disease stage
Required: Stage CT3NX
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiotherapy
No prior anti-cancer treatment (radiotherapy, chemotherapy, targeted therapy, or immunotherapy).
Cannot have received: chemotherapy
No prior anti-cancer treatment (radiotherapy, chemotherapy, targeted therapy, or immunotherapy).
Cannot have received: targeted therapy
No prior anti-cancer treatment (radiotherapy, chemotherapy, targeted therapy, or immunotherapy).
Cannot have received: immunotherapy
No prior anti-cancer treatment (radiotherapy, chemotherapy, targeted therapy, or immunotherapy).
Cannot have received: anti-PD-1 therapy
history of having received anti-PD-1, PD-L1, PD-L2, CTLA-4, or any other specific T-cell costimulatory or checkpoint pathway-targeted therapy
Cannot have received: anti-PD-L1 therapy
history of having received anti-PD-1, PD-L1, PD-L2, CTLA-4, or any other specific T-cell costimulatory or checkpoint pathway-targeted therapy
Cannot have received: anti-PD-L2 therapy
history of having received anti-PD-1, PD-L1, PD-L2, CTLA-4, or any other specific T-cell costimulatory or checkpoint pathway-targeted therapy
Cannot have received: anti-CTLA-4 therapy
history of having received anti-PD-1, PD-L1, PD-L2, CTLA-4, or any other specific T-cell costimulatory or checkpoint pathway-targeted therapy
Lab requirements
Blood counts
white blood cells (wbc) ≥3.0×10^9/l or absolute neutrophil count (anc) ≥1.5×10^9/l; hemoglobin (hgb) ≥80 g/l; platelets (plt) ≥100×10^9/l
Kidney function
creatinine (creat) <1.5 times the upper limit of the normal range
Liver function
liver transaminases (ast/alt) <3.0 times the upper limit of the normal range; total bilirubin (tbil) <1.5 times the upper limit of the normal range
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06908031 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require MMR?
Yes, MMR proficient is a required biomarker for enrollment.
Does this trial require MSH2?
Yes, MSH2 microsatellite stable is a required biomarker for enrollment.
What disease stage is eligible?
Stage CT3NX is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages